Bamlanivimab/etesevimab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Combination of
Bamlanivimab Monoclonal antibody
Etesevimab Monoclonal antibody
Clinical data
Licence data US Daily Med:link
Legal status
Routes of
administration		 Intravenous
Identifiers
ATC code None

Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as a treatment for COVID-19.[1][2][3] Both types of antibody target the surface spike protein of SARS‑CoV‑2.[4][5]

Contents

Etesevimab

Etesevimab
Monoclonal antibody
Type Whole antibody
Source Human
Target Spike protein of SARS-CoV-2
Clinical data
Licence data US Daily Med:link
Routes of
administration		 Intravenous
Identifiers
CAS Number 2423948-94-9
ATC code None
DrugBank DB15897
UNII N7Q9NLF11I
Synonyms LY3832479, LY-CoV016

Etesevimab is a monoclonal antibody against the surface spike protein of SARS‑CoV‑2.[2][4]

Eli Lilly licensed etesevimab from Junshi Biosciences.[2]

Bamlanivimab

<templatestyles src="Module:Hatnote/styles.css"></templatestyles>

Main article: Bamlanivimab

Bamlanivimab is an IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS‑CoV‑2. The aim is to block viral attachment and entry into human cells, thus neutralizing the virus, and help preventing and treating COVID-19.[5]

Trials

The data supporting the emergency use authorization (EUA) for bamlanivimab and etesevimab are based on a randomized, double-blind, placebo-controlled clinical trial in 1,035 non-hospitalized participants with mild to moderate COVID-19 symptoms who were at high risk for progressing to severe COVID-19.[1] Of these participants, 518 received a single infusion of bamlanivimab 2,800 milligrams and etesevimab 2,800 milligrams together, and 517 received placebo.[1] The primary endpoint was COVID-19 related hospitalizations or death by any cause during 29 days of follow-up.[1] Hospitalization or death occurred in 36 (7%) participants who received placebo compared to 11 (2%) participants treated with bamlanivimab 2,800 milligrams and etesevimab 2,800 milligrams administered together, a 70% reduction.[1] All ten deaths (2%) occurred in the placebo group.[1] Thus, all-cause death was significantly lower in the bamlanivimab 2,800-milligram and etesevimab 2,800-milligram group than the placebo group.[1]

Authorization

On 9 February 2021, the FDA issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in people twelve years of age or older weighing at least 40 kilograms (88 lb) who test positive for SARS‑CoV‑2 and who are at high risk for progressing to severe COVID-19. The authorized use includes treatment for those who are 65 years of age or older or who have certain chronic medical conditions. While bamlanivimab and etesevimab administered together resulted in a lower risk of resistant viruses developing during treatment compared with bamlanivimab administered alone, both treatments are available under an EUA and are expected to benefit people at high risk of disease progression.[1] On 16 April 2021, the FDA revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.[6]

The EUA was issued to Eli Lilly and Co.[1]

On 1 February 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started rolling reviews of data on the use of the monoclonal antibodies casirivimab/imdevimab, bamlanivimab/etesevimab, and bamlanivimab for the treatment of COVID-19.[7] In March 2021, the CHMP concluded that bamlanivimab and etesevimab can be used together to treat confirmed COVID-19 in people who do not require supplemental oxygen and who are at high risk of their COVID-19 disease becoming severe.[8] The CHMP also looked at the use of bamlanivimab alone and concluded that, despite uncertainties around the benefits of monotherapy, it can be considered a treatment option.[8]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Lua error in package.lua at line 80: module 'strict' not found.  This article incorporates text from this source, which is in the public domain.
  2. ↑ 2.0 2.1 2.2 Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ 4.0 4.1 Lua error in package.lua at line 80: module 'strict' not found.
  5. ↑ 5.0 5.1 Lua error in package.lua at line 80: module 'strict' not found.
  6. ↑ Lua error in package.lua at line 80: module 'strict' not found.  This article incorporates text from this source, which is in the public domain.
  7. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  8. ↑ 8.0 8.1 Lua error in package.lua at line 80: module 'strict' not found. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

This article incorporates text from the United States Department of Health and Human Services ([1]), which is in the public domain.


External links

Retrieved from "https://infogalactic.com/w/index.php?title=Bamlanivimab/etesevimab&oldid=726235824"